Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walker, C.
Right arrow Articles by Warnke, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, C.
Right arrow Articles by Warnke, P. C.
Clinical Cancer Research Vol. 9, 4841-4851, October 15, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity

Carol Walker1, Daniel G. du Plessis, Kathy A. Joyce, Yvonne Machell, Joanne Thomson-Hehir, Syed A. Al Haddad, John C. Broome and Peter C. Warnke

Clatterbridge Cancer Research Trust, J. K. Douglas Laboratories, Clatterbridge Hospital, Bebington, Wirral, CH63 4JY [C. W., K. A. J., Y. M., J. T-H.]; Walton Centre for Neurology and Neurosurgery, Liverpool, L97LJ [D. G. d. P., J. C. B., P. C. W.]; and Department of Neurological Science, University of Liverpool, Liverpool, L9 7LJ [D. G. d. P., S. A. A. H., P. C. W.], United Kingdom

Purpose: Molecular classification of gliomas is becoming increasingly important clinically as an adjunct to histopathological diagnosis. Whereas histological heterogeneity of gliomas is well recognized, less is known of the relationship between histological heterogeneity and genetic alterations. Our objective was to investigate the relationship between genotype and phenotype for markers of potential clinical utility in histologically heterogeneous gliomas.

Experimental Design: We have used laser capture microdissection to sample the various histological phenotypes present in 42 tumors from 25 glioma cases with either inter- or intratumoral histological heterogeneity, and multiple simultaneous PCR amplification of microsatellite markers and capillary electrophoresis to determine allelic imbalance in chromosomes 1p, 19q, 17p, 10p, and 10q.

Results: Loss of 1p36 and 19q13 was seen only in oligodendroglial histology in 7 of 13 oligodendrogliomas. 17p13 loss was found in 14 of 41 tumors in astrocytic, oligoastrocytic, oligodendroglial, and glioblastomatous histologies. Chromosome 10 loss was seen in all of the high-grade histologies in 7 of 7 glioblastomas with an oligodendroglial component and in 1 of 5 low-grade oligodendroglial regions present within high-grade tumors. Seven tumors from 5 cases had no detectable losses of any markers investigated. In 13 tumors with intratumoral heterogeneity, identical genetic losses were present in all areas of histological differentiation. Additional losses were seen in some but not all of the histologies within 2 tumors and were associated with progression in 3 cases.

Conclusions: The gliomas in this study were more homogeneous in their genotype than their histological phenotype with regions of differing histological subtype indistinguishable by the genetic markers investigated, supporting a monoclonal origin of these tumors.




This article has been cited by other articles:


Home page
NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal
Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas
Clin. Cancer Res., March 1, 2007; 13(5): 1429 - 1437.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
M. D. Jenkinson, D. G. du Plessis, T. S. Smith, K. A. Joyce, P. C. Warnke, and C. Walker
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features
Brain, July 1, 2006; 129(7): 1884 - 1891.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology, June 13, 2006; 66(11): 1661 - 1667.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M. D. Jenkinson, T. S. Smith, K. Joyce, D. Fildes, D. G. du Plessis, P. C. Warnke, and C. Walker
MRS of oligodendroglial tumors: Correlation with histopathology and genetic subtypes
Neurology, June 28, 2005; 64(12): 2085 - 2089.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Walker, D. G. du Plessis, D. Fildes, B. Haylock, D. Husband, M. D. Jenkinson, K. A. Joyce, J. Broome, K. Kopitski, J. Prosser, et al.
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
Clin. Cancer Res., November 1, 2004; 10(21): 7182 - 7191.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.